{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-096920","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2025-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.858035+00:00","generated_at":"2026-05-17T04:32:54.016834+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Traws Pharma appoints John Leaman as independent director, formalizes CEO and CFO titles","bullets":["John Leaman, MD appointed independent director effective Oct 1, 2025; joins Audit Committee.","Interim titles removed: Iain Dukes now CEO, Charles Parker now CFO of Traws Pharma.","Dr. Leaman brings experience as CFO of Cellarity, Impel Pharma, Selecta Biosciences.","Company progressing Phase 2 studies for lead candidate ratutrelvir (COVID-19 treatment).","CFO Charles Parker compensated via Stout at $500/hr, up to $50k/month for services."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-096920","json":"https://secwatch.observer/filing/0001104659-25-096920.json","markdown":"https://secwatch.observer/filing/0001104659-25-096920.md","text":"https://secwatch.observer/filing/0001104659-25-096920.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925096920/0001104659-25-096920-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925096920/tm2528048d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:32:54.016834+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}